Product Name: tert-Butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]piperidine-1-carboxylate CAS 877399-74-1
4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-yl]-piperidin-1-carboxylic acid tert-butyl ester;
Chemical & Physical Properties:
Appearance :white powder
Boiling Point:492.8℃ at 760 mmHg
Crizotinib is a small molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), ROS1, and another oncogene receptor tyrosine kinase MET. Crizotinib capsules can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) determined by the SFDA-approved test method. The approval of this indication is mainly based on the objective response rate (ORR) and progression-free survival (PFS) evidence. At present, there is no evidence of survival benefit (OS) of this product.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.